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Abstract
Rationale Long-acting injectable antipsychotic therapies may
offer benefits over oral antipsychotics in patients with
schizophrenia.
Objective This study aimed to explore the safety, tolerability,
and treatment response of paliperidone palmitate once-
monthly in non-acute but symptomatic adult patients switched
from previously unsuccessful monotherapy with frequently
used oral atypical antipsychotics.
Methods This was a post hoc analysis of a prospective, inter-
ventional, single-arm, international, multicenter, open-label,
6-month study.
Results The patients (N = 472) were switched to paliperidone
palmitate once-monthly (PP1M) from daily oral treatment
with either aripiprazole (n = 46), olanzapine (n = 87),
paliperidone extended-release (n = 104), quetiapine (n = 44),
or risperidone (n = 191). In all groups, mean Positive and
Negative Syndrome Scale total (p < 0.0001) and Clinical
Global Impression-Severity scores improved significantly
(p = 0.0004 to p < 0.0001). An improvement of ≥50 % in the
Positive and Negative Syndrome Scale total score was observed
in 21.7 % (aripiprazole), 29.9 % (olanzapine), 29.8 %
(paliperidone extended-release), 27.3 % (quetiapine), and
37.2 % (risperidone) of patients. The patients showed significant
improvements in the Personal and Social Performance score
(aripiprazole p = 0.0409, all others p ≤ 0.0015); Mini
International Classification of Functionality, Disability and
Health Rating for Activity and Participation Disorders in
Psychological Illnesses total scores (all p < 0.01); and
Treatment Satisfaction Questionnaire for Medication Global
Satisfaction score (olanzapine and risperidone p < 0.0001,
quetiapine p = 0.0465, paliperidone extended-release
p = 0.0571, aripiprazole p = NS). Paliperidone palmitate once-
monthly was well tolerated, presenting no new safety signals.
Conclusions These data illustrate that stable, non-acute but
symptomatic patients on oral antipsychotic monotherapy
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may show clinically meaningful improvement of symptoms,
functioning, and treatment satisfaction after direct transition to
PP1M. The findings are limited by the naturalistic study de-
sign; thus, further studies are required to confirm the current
findings.
Keywords Functioning . Non-acute . Long-acting injectable
antipsychotic therapy . Oral antipsychotic . Paliperidone
palmitate . Switching . Schizophrenia . Treatment satisfaction
Introduction
Pharmacotherapy, which includes oral and long-acting inject-
able (LAI) antipsychotics, remains the mainstay treatment in
schizophrenia (Hasan et al. 2013); nevertheless, discontinua-
tion rates are high (Kahn et al. 2008; Lieberman et al. 2005;
Naber and Lambert 2009). Clinical practice guidelines strong-
ly recommended antipsychotic monotherapy for the treatment
of schizophrenia (Barnes 2011; Lerma-Carrillo et al. 2008;
National Institute for Health and Care Excellence (NICE)
2014).
Oral atypical antipsychotics generally have the same overall
efficacy but differ in their side effect profiles, with apparent
differences in sedation, metabolic disturbances such as weight
gain, glucose and lipid abnormalities, and the risk of extrapy-
ramidal motor symptoms (EPMSs) (Davis et al. 2003; De Hert
et al. 2012; Jones et al. 2010; Leucht et al. 2013; Rummel-
Kluge et al. 2010). Non-adherence to antipsychotic medication
is associated with increased risk of relapse and hospitalization
at all stages of schizophrenia (Kozma and Weiden 2009;
Leucht and Heres 2006; Llorca 2008; Robinson et al. 1999),
and may be influenced by several factors (Tandon et al. 2006),
including poor efficacy (worsening of symptoms) (Liu-Seifert
et al. 2005) and the presence of side effects (Higashi et al.
2013).
LAI antipsychotic therapy (LAT) may improve adherence
to medication in patients with schizophrenia (Cañas et al.
2013) and, as a consequence, significantly reduce relapse rates
and improve long-term outcomes compared with those treated
with oral antipsychotic medication (Leucht et al. 2011;
Tiihonen et al. 2011). A systematic review and meta-analysis
of mirror-image studies comparing a period of treatment using
oral antipsychotics with a subsequent period of treatment
using LAT within the same patient showed that LATs were
significantly superior in reducing relapse rates compared with
oral antipsychotics (Kishimoto et al. 2013); however, this out-
come was in contrast to a recent meta-analysis based on ran-
domized controlled trials (RCTs) comparing LATs and oral
antipsychotics (Kishimoto et al. 2014). The short duration of
the majority of RCTs, the very defined patient inclusion
criteria, and the added care and close follow-up of patients
suggest that such studies do not adequately reflect real clinical
practice or treatment of patients with schizophrenia in the
community, and therefore longer, naturalistic studies are re-
quired (Olivares et al. 2009b). Consequently, it has been
shown that the outcomes of studies comparing oral antipsy-
chotics and LATs are sensitive to trial design, and RCTs are
not optimal for exploring differences between oral antipsy-
chotics and LATs (Alphs et al. 2014; Kirson et al. 2013).
Since treatment response and side effect profiles vary be-
tween different antipsychotics (Jones et al. 2010; Leucht et al.
2013; Taylor et al. 2012), it is of particular interest to explore
treatment response, safety, and tolerability in patients previ-
ously unsuccessfully treated with oral atypical antipsychotic
monotherapy who were switched to LAT in a routine clinical
setting. Paliperidone palmitate once-monthly (PP1M) is an
atypical LAT designed for intramuscular (IM) administration
indicated for the maintenance treatment of adult patients with
schizophrenia (Janssen Cilag 2015).
The Paliperidone Palmitate Flexible Dosing in
Schizophrenia (PALMFlexS) study was a prospective, 6-
month, pragmatic, interventional study conducted in a large,
more representative sample of patients with schizophrenia
than those recruited in the pivotal RCTs (Hargarter et al.
2015; Schreiner et al. 2015b; Schreiner et al. 2014a). The
study was designed specifically to reflect more closely real-
world clinical situations in which the transition to another
antipsychotic is performed in previously unsuccessfully treat-
ed patients. The PALMFlexS study included three distinct
patient populations: patients with non-acute schizophrenia
switching to PP1M from oral antipsychotics, non-acute pa-
tients switching to PP1M from other LATs, and acute patients
switching to PP1M from oral antipsychotics.
To understand the impact of dosing and switching
strategies when initiating PP1M, the current analysis
was conducted in non-acute but symptomatic patients
with schizophrenia switched from previously unsuccess-
ful monotherapy with the most frequently used oral
atypical antipsychotics.
Materials and methods
This was a post hoc analysis of a prospective, interventional,
single-arm, multicenter, open-label, 6-month study performed
in patients with schizophrenia from 160 centers across 21
countries between November 2010 and November 2012
(NCT01281527). The study was performed in accordance
with the Declaration of Helsinki and was consistent with
Good Clinical Practices of the International Conference on
Harmonisation and applicable regulatory requirements. All
the patients provided informed written consent.
The protocol, full details of the study population, and over-
all results have previously been reported (Schreiner et al.
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2014a). Methods that are specific to this post hoc analysis are
briefly described below.
Study design and patients
Non-acute but symptomatic male or female patients aged
≥18 years with schizophrenia (diagnosed according to the
Diagnostic and Statistical Manual of Mental Disorders, Fourth
Edition criteria), who were previously unsuccessfully treated
using oral monotherapy with either aripiprazole (ARI),
olanzapine (OLA), paliperidone extended-release (Pali ER),
quetiapine (QUE), or risperidone (RIS), were selected from the
overall study population of PALMFlexS (Schreiner et al. 2014a).
The patients were required to be “stable” but symptomatic,
i.e., have been on the same oral atypical antipsychotic mono-
therapy for the treatment of schizophrenia on an adequate ther-
apeutic dose and with a change in the Clinical Global
Impression-Severity (CGI-S) score of ≤1 for ≥4 weeks prior
to enrolment. Their current treatment was considered to have
been unsuccessful due to one or more of the following reasons:
lack of efficacy (baseline Positive and Negative Syndrome
Scale [PANSS] total score ≥70 or ≥2 items scoring ≥4 in the
PANSS positive or negative subscale or ≥3 items scoring ≥4 in
the PANSS general psychopathology subscale, as judged by the
investigator), lack of tolerability or safety (defined as the pres-
ence of intolerable [according to the patient] and/or clinically
relevant [according to the investigator] side effects on their
current antipsychotic medication), lack of adherence, or pa-
tient’s wish. Lack of adherence was assessed individually by
the investigator. There were no specific protocol-defined
criteria. Patients were excluded if, at the discretion of the inves-
tigator, their diagnosis was considered to be the direct result of
the pharmacological effects of a substance or general medical
condition, they were treatment naïve, they had received cloza-
pine within 3 months prior to the start of the study, they were
considered at imminent risk of suicide even after clinical inter-
vention, they had a history of or current symptoms of tardive
dyskinesia or neuroleptic malignant syndrome, they were preg-
nant or breastfeeding, or they had any known allergies to RIS or
paliperidone or any of its excipients. The inclusion/exclusion
criteria were designed to recruit a more diverse study popula-
tion than those in previously conducted pivotal studies (Gopal
et al. 2010; Pandina et al. 2010); for example, patients with
relevant comorbidities, co-medications, and current substance
use or abuse, with the exception of intravenous drug use, were
eligible for enrolment and there were no exclusions based on
body mass index (BMI).
In the present study, the patients were switched directly to
PP1M, in line with the indication and posology of PP1M
European summary of product characteristics (Janssen Cilag
2015). After initiation of PP1M, the patients were tapered off
their oral atypical antipsychotic at the discretion of the treating
physician, preferably within a maximum of 4 weeks. PP1M
was initiated, in line with the SmPC, at a recommended dose
of 150 mg equivalent (mg eq) on day 1 and 100 mg eq on day
8 (±2 days; nota bene, the current summary of product char-
acteristics now states ±4 days) intramuscularly, both given in
the deltoid muscle. Subsequently, PP1M was administered
once-monthly (±7 days) (visit days) using flexible mainte-
nance dosages within the range of 50 to 150 mg eq based on
the clinical judgment of the treating physician. Patients with-
out documentation of previous RIS or paliperidone exposure
were tested for tolerability with Pali ER (3 mg/day) for at least
2 days prior to receiving PP1M. Efficacy, tolerability, and
safety were assessed by the same person at each study visit,
whenever possible.
Efficacy assessments
Efficacy outcomeswere assessed after 6months of treatment by
trained, qualified, non-blinded assessors. Evaluation time
points were days 1 (baseline), 8, 38 (month 1), 68 (month 2),
98 (month 3), 128 (month 4), 158 (month 5), and 188 (month
6). The primary efficacy outcome for non-acute but symptom-
atic patients with schizophrenia switched due to lack of efficacy
was the percentage of patients achieving treatment response,
defined as ≥20 % improvement in PANSS total score from
baseline to endpoint (6 months or time of early discontinua-
tion). Maintained efficacy (defined as non-inferiority in
the change in PANSS total score at endpoint versus baseline,
as measured by means of Schuirmann’s test) was the primary
efficacy outcome for patients switched to PP1M for other
reasons. Actual scores and change from baseline in CGI-S
score, Personal and Social Performance (PSP) scale (Morosini
et al. 2000) total score, Mini International Classification of
Functionality, Disability and Health (ICF) Rating for Activity
and Participation Disorders in Psychological Illnesses
(Mini-ICF-APP) (Linden and Baron 2005; Molodynski et al.
2013), and treatment satisfaction (assessed in patients using the
14-item Treatment Satisfaction Questionnaire for Medication
[TSQM] scale (Atkinson et al. 2004) and physician treatment
satisfaction using a 7-point categorical scale) scores were also
analyzed.
Safety and tolerability
All treatment-emergent adverse events (TEAEs), defined as
adverse events that were new in onset or were aggravated in
severity following initiation of PP1M, were documented at
each clinic visit and coded using the Medical Dictionary for
Regulatory Activities (version 13.0). EPMSs were assessed
by the Extrapyramidal Symptom Rating Scale (ESRS)
(Chouinard and Margolese 2005). In addition, alcohol and
substance use were measured using the Clinician Rating
Alcohol Use Scale (CRAUS) and the Clinician Rating
Substance Use Scale (CRSUS) (Carey et al. 1996). Body
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weight was recorded at each assessment point and endpoint,
and BMI was calculated. There were no obligatory protocol-
based prolactin measurements; however, investigators were
allowed to measure prolactin levels at any time during the
study at their own discretion.
Data analysis
The intent-to-treat (ITT) population comprised all patients who
received PP1M at least once. Analysis of treatment response
was performed on the efficacy analysis population, which in-
cluded all ITT patients with at least one post-baseline efficacy
assessment. Endpoint analysis using the last observation carried
forward (LOCF) method was performed in addition to observed
case analysis. Actual values and changes from baseline were
summarized descriptively at each assessment time point and at
the patient’s last evaluation (endpoint) while categorical vari-
ables were summarized with frequency and percentage.
Within-group changes in efficacy parameters from baseline to
endpoint were analyzed using the Wilcoxon signed-rank test.
Between-oral-subgroup differences were tested using Fisher’s
exact test and the Kruskal–Wallis test. All tests were performed
using Statistical Analysis System version 9.2.
Safety and tolerability were evaluated throughout the study
on the safety ITT population, which comprised all ITT patients
who had at least one post-baseline safety observation. TEAE
frequency distributions included severity of events (i.e., mild,
moderate, or severe) and causal relationship to treatment (i.e.,
not related, doubtful, possible, probably, or very likely).
Results
Demographics and patient disposition
In total, 472 non-acute patients with schizophrenia were eligi-
ble for this analysis. Patients enrolled in the study were on a
stable oral atypical antipsychotic dose at enrolment (Table 1).
The reasons for patients to switch from their current oral atyp-
ical antipsychotic to PP1Mwere patient’s wish (45 %), lack of
efficacy (22 %), and lack of compliance (25 %).
Patient disposition is described in Fig. 1. Baseline charac-
teristics are summarized in Table 1. There were non-
significant between-group differences in mean age (standard
deviation [SD]; ranging from 34.4 [9.4] years [ARI] to 40.8
[11.7] years [QUE]), mean body weight (79.7 [17.3] kg [RIS]
to 89.1 [22.1] kg [ARI]), and percentage of males in the group
(50.0 % [QUE] to 73.9 % [ARI]) at baseline (Table 1). At
baseline, 39 (9.3%) patients were reported to have a diagnosis
of substance abuse (with or without impairment).
Following the day 1 (150mg eq)/day 8 (100mg eq) initiation
regimen, the PP1M mean modal maintenance dose from the
third injection onwards ranged from 94.9 (35.0) mg eq for
patients who switched from ARI to 105.0 (36.8) mg eq for
patients who switched from QUE; the final dose distribution of
PP1M is summarized in Table 1. Regardless of the oral antipsy-
chotic that patients were switched from, most (92.3 % [Pali ER]
to 97.7 % [QUE]) received PP1M according to the recommend-
ed initiation regimen. Overall, 72.8 % of patients had a dose
adjustment after the third dose of PP1M, with the majority re-
quiring only one adjustment (ARI 45.7%, OLA 54.0%, Pali ER
49.0 %, QUE 45.5 %, RIS 50.8 %). The percentage of patients
with one or more dose increase varied from 36.5 % (Pali ER) to
45.5 % (QUE), and the percentage of patients with one or more
dose decrease varied from 38.6 % (QUE) to 55.8 % (Pali ER).
The proportion of patients using concomitant medications
(benzodiazepines and anticholinergics) during the study is
shown in Table 1.
Efficacy outcomes
At endpoint, of all patients that switched from previous atyp-
ical oral monotherapy to PP1M, 52.2% (ARI), 60.9% (OLA),
57.7 % (Pali ER), 65.9 % (QUE), and 73.8 % (RIS) had a
≥20% improvement in PANSS total score. In addition, 21.7%
(ARI), 29.9 % (OLA), 29.8 % (Pali ER), 27.3 % (QUE), and
37.2 % (RIS) of patients had a ≥50 % improvement in PANSS
total score. The mean PANSS total score was significantly
improved from baseline to endpoint in all groups
(p < 0.0001) (Fig. 2). Disease severity, as measured by the
mean CGI-S score, improved significantly from baseline to
endpoint in all groups (p = 0.0004 to p < 0.0001) (Table 2).
Secondary outcomes
At endpoint, patients who were switched from atypical oral
antipsychotics to PP1M showed a statistically significant im-
provement from baseline in PSP total scores (p = 0.0409 for
ARI to p < 0.0001 for RIS, Pali ER, andQUE) and inMini-ICF-
APP total score (p = 0.0079 for ARI to p < 0.0001 for RIS and
Pali ER) (Table 2). Significant improvements from baseline to
endpoint in TSQM Global Satisfaction score were observed in
patients who switched from OLA (p < 0.0001), QUE
(p = 0.0465), and RIS (p < 0.0001) and in patients who switched
from Pali ER (p = 0.0571). There was no significant difference
in TSQM Global Satisfaction score between ARI and PP1M.
Overall, physician treatment satisfaction improved significantly
from baseline to endpoint in all groups (p < 0.0001) (Table 2).
Safety and tolerability
TEAEs affecting ≥5 % of patients in any group are summa-
rized in Table 3. Mean change in the ESRS total score (SD)
from baseline to endpoint was −0.6 (3.4) for ARI, −1.3 (4.4)
for OLA, −0.7 (4.1) for Pali ER, −0.3 (3.2) for QUE, and −1.2
(3.5) for RIS (p < 0.05 for all, except QUE p = 0.4857)
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(Fig. 3). Mean weight change (SD) from baseline to endpoint
ranged between −0.3 (4.6) kg for OLA (95 % confidence
interval [CI] –1.3, 0.7) and 3.5 (6.3) kg for ARI (95 % CI
1.5, 5.4) (Supplementary Table 1). Mean changes in BMI
from baseline to endpoint were similar, ranging from
−0.1 (1.6) kg/m2 for OLA (95 % CI −0.5, 0.3) to 1.2
(2.2) kg/m2 for ARI (95 % CI 0.5, 1.9) (Supplementary
Table 1).
Table 1 Baseline characteristics and PP1M dosing (N = 472)
Patients switched to PP1M from ARI OLA Pali ER QUE RIS p value
ITT population, n 46 87 104 44 191
Mean age, years (SD) 34.4 (9.4) 36.8 (11.6) 37.7 (11.7) 40.8 (11.7) 38.7 (12.5) 0.0773a
Male, % 73.9 67.8 70.2 50.0 61.8 0.0861b
Mean age at diagnosis, years (SD) 27.6 (6.7) 28.4 (9.7) 29.0 (9.5) 30.7 (10.3) 30.7 (10.4)
Diagnosis of paranoid schizophrenia, % 78.3 79.3 81.7 72.7 74.9
Mean baseline weight, kg (SD) 89.1 (22.1) 79.8 (16.4) 80.0 (17.3) 80.4 (16.0) 79.7 (17.3) 0.1018a
Mean baseline BMI, kg/m2 (SD; range) 29.9 (7.5; 17, 51) 27.2 (6.1; 18, 46) 27.0 (5.5; 17, 51) 28.1 (5.3; 18, 39) 27.0 (5.5; 17, 54) 0.1120a
Patients with ≥1 comorbidity, %c 78.3 63.2 58.7 52.3 59.2
Number of previous hospitalizations, %
None 10.9 18.4 21.2 18.2 19.9
1–3 45.7 47.1 35.6 36.4 48.7
≥4 43.5 34.5 43.3 45.5 31.4
Patients with diagnosed substance abuse
(with or without impairment), %
9.8 10.5 6.4 5.4 11.1
Mean daily dose of prior antipsychotic,
mg (SD)
22.7 (10.7) 15.6 (8.2) 7.6 (2.6) 482.4 (277.1) 4.3 (2.3)
Patients receiving PP1M initiation regimen
at day 1 and day 8 according to label, %d
93.5 95.4 92.3 97.7 96.3
Mean modal PP1M maintenance dose,
mg eq (SD)e
94.9 (35.0) 104.2 (33.6) 100.5 (32.3) 105.0 (36.8) 98.9 (32.3)
Last PP1M dose received, % of patients
50 mg eq 19.6 6.9 8.7 13.6 8.4
75 mg eq 19.6 32.2 32.7 15.9 35.1
100 mg eq 30.4 31.0 35.6 40.9 33.0
150 mg eq 30.4 29.9 23.1 29.5 23.6
Relevant co-medications
Number (%) of patients using benzodiazepines
At baseline 12 (26.1) 25 (28.7) 28 (26.9) 9 (20.5) 39 (20.4)
Newly initiated during study 11 (23.9) 21 (24.1) 26 (25.0) 14 (31.8) 30 (15.7)
At endpoint 12 (26.1) 21 (24.1) 21 (20.2) 8 (18.2) 36 (18.8)
At 6 months for completersf 9 (29.0) 10 (17.5) 15 (18.1) 6 (18.8) 29 (18.2)
Number (%) of patients using anticholinergics
At baseline 2 (4.3) 8 (9.2) 10 (9.6) 4 (9.1) 23 (12.0)
Newly initiated during study 2 (4.3) 9 (10.3) 7 (6.7) 4 (9.1) 14 (7.3)
At endpoint 2 (4.3) 8 (9.2) 5 (4.8) 4 (9.1) 14 (7.3)
At 6 months for completersf 2 (6.5) 5 (8.8) 4 (4.8) 2 (6.3) 12 (7.5)
ARI aripiprazole, BMI body mass index, ITT intent to treat, OLA olanzapine, Pali ER paliperidone extended-release, PP1M once-monthly paliperidone
palmitate, QUE quetiapine, RIS risperidone, SD standard deviation. p values indicate differences between prior oral antipsychotic treatment subgroups
a Kruskal–Wallis test
b Fisher’s exact test
c Individual patients can be labelled for >1 comorbidity
d The recommended initiation regimen was PP1M 150 mg eq on day 1 and 100 mg eq on day 8, given in the deltoid muscle
e Excluding the initiation regimen (day 1/day 8)
f ARI n = 31; OLA n = 57; Pali ER n = 83; QUE n = 32; RIS n = 159
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Fig. 1 Patient disposition. *patients who received at least one dose of study drug. ARI aripiprazole, ITT intent to treat, OLA olanzapine, PP1M once-
monthly paliperidone palmitate, Pali ER paliperidone extended-release, QUE quetiapine, RIS risperidone
Fig. 2 Mean PANSS total score over time (efficacy ITT population;
N = 472). p < 0.001 vs baseline for all antipsychotics. ARI aripiprazole,
BL baseline, ITT intent to treat, OLA olanzapine, PANSS Positive and
Negative Syndrome Scale, PP1M once-monthly paliperidone palmitate,
Pali ER paliperidone extended-release, QUE quetiapine, RIS risperidone.
***p <0.0001 vs baseline for all antipsychotics
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Investigators reported hyperprolactinemia in two patients
in the OLA group and three patients in the prior Pali ER group
and an increase in blood prolactin in two patients in the prior
ARI group.
Of 1058 PALMFlexS patients, 177 did not have source
documentation on PP1M/RIS exposure. A total 172 patients
tolerated the oral tolerance test well, two patients did not, and
in three patients, the test result was not available.
Table 2 Secondary efficacy outcomes (efficacy ITT population; N = 472)
Patients switched to PP1M from ARI OLA Pali ER QUE RIS
Mean PANSS total score, n 44 87 104 44 191
Baseline (SD) 74.7 (14.9) 71.4 (13.2) 71.3 (14.3) 70.8 (13.1) 70.8 (15.1)
Endpoint (SD) 62.6 (16.5) 62.3 (19.6) 60.4 (17.2) 60.5 (20.1) 56.9 (17.3)
Mean change from baseline
to endpoint (SD)
−12.2 (16.7) −9.1 (17.5) −10.8 (14.4) −10.2 (19.6) −13.9 (14.8)












Mean CGI-S score, na 46 86 104 44 189
Baseline (SD) 4.1 (0.8) 3.7 (1.0) 3.9 (0.9) 3.9 (0.9) 3.8 (0.9)
Endpoint (SD) 3.5 (1.0) 3.3 (1.2) 3.4 (1.1) 3.4 (1.0) 3.0 (1.0)
Mean change from baseline
to endpoint (SD)
−0.6 (1.1) −0.4 (1.1) −0.6 (1.1) −0.5 (1.1) −0.8 (0.9)












Mean PSP score, na 44 84 103 44 185
Baseline (SD) 58.9 (13.4) 61.5 (14.6) 58.3 (13.7) 56.3 (12.0) 57.8 (12.3)
Endpoint (SD) 62.9 (15.2) 66.0 (17.7) 65.4 (16.4) 64.2 (15.9) 68.2 (13.9)
Mean change from baseline
to endpoint (SD)
3.9 (13.2) 4.5 (15.9) 7.0 (13.8) 7.9 (12.4) 10.4 (13.8)












Mean Mini-ICF-APP total score, nc 43 79 97 42 179
Baseline (SD) 19.0 (7.8) 18.1 (8.8) 19.9 (8.5) 21.6 (6.9) 19.9 (7.0)
Endpoint (SD) 16.1 (9.8) 15.3 (9.5) 16.8 (9.6) 17.8 (8.7) 14.7 (7.3)
Mean change from baseline
to endpoint (SD)
−2.9 (7.1) −2.8 (7.8) −3.1 (7.3) −3.8 (9.2) −5.2 (7.1)












Physician overall treatment satisfaction, n 41 76 94 38 172
Baseline (SD) 4.5 (1.1) 4.1 (1.2) 3.1 (1.0) 4.1 (1.1) 3.9 (1.1)
Endpoint (SD) 2.8 (1.1) 2.7 (1.2) 2.4 (1.0) 2.7 (1.3) 2.2 (0.9)
Mean change from baseline
to endpoint (SD)
−1.7 (1.5) −1.4 (1.6) −0.7 (1.3) −1.4 (1.6) −1.7 (1.4)












Patient global treatment satisfaction
(TSQM), n
35 73 90 34 166
Baseline (SD) 58.8 (22.1) 55.5 (20.8) 60.2 (22.8) 54.2 (21.7) 54.1 (19.5)
Endpoint (SD) 57.6 (25.2) 68.6 (24.4) 64.9 (22.5) 63.7 (24.2) 67.1 (24.4)
Mean change from baseline
to endpoint (SD)
−1.2 (32.2) 13.1 (26.0) 4.8 (24.7) 9.5 (28.9) 13.1 (30.0)












Only patients with a valid baseline measurement and at least one valid follow-up assessment were included
ARI aripiprazole;CGI-SClinical Global Impression-Severity;CI confidence interval; ITT intent to treat;Mini-ICF-APPMini International Classification
of Functionality, Disability and Health Rating for Activity and Participation Disorders in Psychological Illnesses;OLA olanzapine; Pali ER paliperidone
extended-release; PANSS Positive and Negative Syndrome Scale; PP1M once-monthly paliperidone palmitate; PSP Personal and Social Performance;
QUE quetiapine; RIS risperidone; SD standard deviation; TSQM Treatment Satisfaction Questionnaire for Medication
a For the CGI-S a lower score indicates improvement; For the PSP, a higher score indicates improvement
bWithin-group difference was tested using the Wilcoxon signed-rank test
c For the Mini-ICF-APP, a lower score indicates improvement
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Discussion
In this analysis, patients with non-acute schizophrenia who
were switched from oral atypical antipsychotic monotherapy
to PP1M demonstrated significant and clinically relevant
improvements in psychotic symptoms and functioning, re-
gardless of the previous oral atypical antipsychotic
monotherapy.
At baseline, patients were mildly to moderately symptomatic,
and as such, they could be considered stable but sub-optimally
Table 3 Treatment-emergent adverse events (safety ITT population; N = 472)
Patients switched to PP1M from ARI (n = 46) OLA (n = 87) Pali ER (n = 104) QUE (n = 44) RIS (n = 191)
Total number of TEAEsa 135 178 158 104 241
Mild (%) 74 (54.8) 112 (62.9) 106 (67.1) 53 (51.0) 134 (55.6)
Moderate (%) 52 (38.5) 56 (31.5) 43 (27.2) 46 (44.2) 87 (36.1)
Severe (%) 9 (6.7) 10 (5.6) 9 (5.7) 5 (4.8) 20 (8.3)
Subjects with ≥1 TEAEa, n (%) 24 (52.2) 45 (51.7) 39 (37.5) 19 (43.2) 53 (27.7)
TEAEsa occurring in ≥5 % of patients in any group, n (%)
Injection-site pain 3 (6.5) 12 (13.8) 15 (14.4) 7 (15.9) 16 (8.4)
Akathisia 4 (8.7) 5 (5.7) 5 (4.8) 2 (4.5) 5 (2.6)
Somnolence 2 (4.3) 5 (5.7) 2 (1.9) 4 (9.1) 4 (2.1)
Abnormal weight gainb 3 (6.5) 1 (1.1) 0 (0.0) 2 (4.5) 3 (1.6)
Weight increasedb 3 (6.5) 1 (1.1) 3 (2.9) 4 (9.1) 3 (1.6)
Insomnia 0 (0.0) 7 (8.0) 1 (1.0) 2 (4.5) 2 (1.0)
Psychotic disorders 1 (2.2) 6 (6.9) 4 (3.8) 1 (2.3) 1 (0.5)
ARI aripiprazole, ITT intent to treat, MedDRA Medical Dictionary for Regulatory Activities, OLA olanzapine, Pali ER paliperidone extended-release,
PP1M once-monthly paliperidone palmitate, QUE quetiapine, RIS risperidone, TEAE treatment-emergent adverse event
a Possibly, probably, or very likely related to PP1M treatment
b Based on the MedDRA coding system, both terms were applicable for coding of TEAEs. None of the identified subjects were recorded under both
terms simultaneously
Fig. 3 Mean ESRS total score over time (safety ITT population;
N = 472). ARI aripiprazole, BL baseline, ESRS Extrapyramidal
Symptom Rating Scale, ITT intent to treat, OLA olanzapine, PP1M
once-monthly paliperidone palmitate, Pali ER paliperidone extended-
release, QUE quetiapine, RIS risperidone p values represent are for
change from baseline to endpoint, Wilcoxon-signed-rank test
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controlled. After 6 months of treatment with PP1M, over half of
all patients showed a treatment response, defined a priori as a
reduction in total PANSS score of ≥20 %, which represents a
clinically meaningful improvement (Cook et al. 2002) for non-
acute patients. Improved efficacy of ≥20 % was specified as the
primary endpoint in this subgroup of patients, as they were
considered previously stable by their treating physician for at
least 1 month prior to enrolment while being prescribed an
adequate dose of an oral atypical antipsychotic monotherapy.
Therefore, the improvement would not be expected to be com-
parable with what generally would be observed in acutely ill
patients, where ≥30 or ≥50 % improvements in PANSS total
score are considered more adequate (Leucht 2014; Leucht et al.
2005). Nevertheless, a ≥50 % reduction in PANSS total score
was achieved by approximately one quarter of patients. The
present results are consistent with a recent naturalistic study
where patients previously unsuccessfully treated with oral anti-
psychotic medications were switched to an atypical LAT (RIS)
and showed significant improvements in hospitalization days
and psychotic symptoms (Schreiner et al. 2014b). However,
between 17 and 32 % of patients who were unsuccessfully
treated with other LAI antipsychotics achieved a ≥50 % im-
provement in their PANSS total score after switching to PP1M
(Schreiner et al. 2015b).
PP1Mmaintenance doseswere relatively homogeneously dis-
tributed across the groups independent of the previous oral anti-
psychotic and in linewith those expected based on the priormean
oral doses.Exceptionswere thehighermaintenancedoses follow-
ing a switch from QUE, possibly to compensate for the loss of
sedating effects and the lower maintenance doses in patients with
prior ARI use, who represented the youngest patients and those
with the shortest timesincediagnosis,whowere therefore likely to
require relatively lower antipsychotic doses.
Differential outcomes were observed in efficacy, function-
ing, EPMS improvement, and weight gain, depending on the
previous oral antipsychotic monotherapy received prior to
switching to PP1M and consistent with the heterogeneity
existing within the group of atypical antipsychotics. When
patients were assessed according to previous oral antipsychot-
ic monotherapy, improvements in efficacy and functioning
scores were numerically greater for those patients who
switched to PP1M from RIS than from other oral antipsy-
chotics. With regard to EPMS, patients from all groups other
than QUE experienced significant improvements, with the
greatest improvements observed for those patients switching
from oral RIS and OLA. Patients switching to PP1M from
previous oral monotherapy with QUE and ARI showed great-
er weight gain compared with other oral antipsychotic switch
groups. However, caution should be exercised when
interpreting these differences as these were exploratory
analyses only and the choice of the previous oral anti-
psychotic medication actually may have been influenced
by the propensity of a patient to develop weight gain or
EPMS, which would be supported by the observation
that patients previously treated with oral ARI had the
highest baseline body weight and BMI.
The current analysis supports the results from previous
fixed-dose RCTs and confirms the efficacy of PP1M in the
treatment of schizophrenia (Gopal et al. 2010; Pandina et al.
2010), and further expands on results from retrospective and
prospective studies in stabilized patients with schizophrenia
that demonstrated improvements in clinical symptoms and
functioning when switched from an oral to a long-acting anti-
psychotic medication (Möller et al. 2005; Olivares et al.
2009a; Rosa et al. 2012), as well as from a LAI antipsychotic
to PP1M (Schreiner et al. 2015b).
Poor adherence to antipsychotic medication impacts the
management of schizophrenia; therefore, strategies aimed at
improving treatment adherence are important to achieve opti-
mal long-term clinical outcomes (Cañas et al. 2013). LAI anti-
psychotics offer a number of potential benefits in long-term
maintenance treatment of patients with schizophrenia, provid-
ing assured delivery of medication, regular contact with the
healthcare team, and transparency about the treatment schedule,
as healthcare professionals will immediately be aware if a pa-
tient misses a dose appointment (Cañas et al. 2013). A recent
Italian survey reported that psychiatrists consider that switching
patients to a LAI antipsychotic is a suitable approach to im-
prove adherence in patients who are not optimally controlled
with an oral atypical antipsychotic (de Bartolomeis et al. 2016).
In this context, the findings from the current analysis provide
evidence of the potential impact of switching to LAT with
paliperidone palmitate in a real-world setting with a heteroge-
neous patient population representative of clinical practice.
Naturalistic studies such as this one reflect everyday clini-
cal settings more accurately than RCTs but are subject to a
number of limitations that should be kept in mind when
interpreting the findings. The study was not designed to detect
differential effects of previous oral antipsychotic monotherapy
on patient outcomes, and therefore, the post hoc data present-
ed herein with respect to such data should be considered ex-
ploratory in nature. Instead, a prospective pragmatic study
design would enable analyses of the effectiveness and safety
of PP1M when switching from different oral antipsychotic
monotherapies. The study was open-label with no active com-
parator group, and as such, these data do not provide a head-
to-head comparison between treatments; rather, they suggest
that failure with one antipsychotic medication does not predict
failure with another. Increased time spent in the study and with
healthcare professionals may have added to the observed im-
provement in outcomes.
Other limitations associated with an open-label design also
impact the interpretation and generalizability of the study re-
sults. As neither the patients nor their physicians were blinded
to the change in antipsychotic treatment, potential bias may
have been introduced, affecting both patient- and physician-
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reported subjective outcome measures (such as PANSS and
PSP scores, and both patient and physician treatment satisfac-
tion scores).
Although this particular study did not have an oral
control group, a recent relapse prevention study showed
that in patients recently diagnosed with schizophrenia,
treatment with PP1M almost doubled the time to relapse
compared with treatment with oral antipsychotics
(Schreiner et al. 2015a). The present study provides im-
portant information about the potential expectations for
treatment outcomes in a clinically representative popula-
tion (many of whom would not have been eligible for
inclusion in RCTs) after switching from atypical oral
antipsychotic monotherapy to PP1M in a more real-
world environment, and includes clinically relevant in-
sights into dosage selection and adjustments and the use
of concomitant medication.
Conclusions
In conclusion, these data illustrate that non-acute pa-
tients (considered clinically stable by their physician)
with schizophrenia may show meaningful improvement
of psychotic symptoms, functioning, and treatment sat-
isfaction when switched from oral atypical antipsychotic
monotherapy to long-acting treatment with PP1M.
However, this open-label, naturalistic study did not have
an oral control group, limiting the strength of these
findings. Validation of these observations in a blinded
study with suitable comparator group(s) would be a
valuable next step. In this diverse patient population,
PP1M was well tolerated, presenting no new safety
signals.
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